294 related articles for article (PubMed ID: 33539852)
61. Lipid-based pulmonary delivery system: a review and future considerations of formulation strategies and limitations.
Ngan CL; Asmawi AA
Drug Deliv Transl Res; 2018 Oct; 8(5):1527-1544. PubMed ID: 29881970
[TBL] [Abstract][Full Text] [Related]
62. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation.
Bhatia A; Kumar R; Katare OP
J Pharm Pharm Sci; 2004 Jul; 7(2):252-9. PubMed ID: 15367383
[TBL] [Abstract][Full Text] [Related]
63. Stability of liposomal formulations in physiological conditions for oral drug delivery.
Taira MC; Chiaramoni NS; Pecuch KM; Alonso-Romanowski S
Drug Deliv; 2004; 11(2):123-8. PubMed ID: 15200011
[TBL] [Abstract][Full Text] [Related]
64. Lipid nanoparticles as drug/gene delivery systems to the retina.
del Pozo-Rodríguez A; Delgado D; Gascón AR; Solinís MÁ
J Ocul Pharmacol Ther; 2013 Mar; 29(2):173-88. PubMed ID: 23286300
[TBL] [Abstract][Full Text] [Related]
65. Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil.
Al Asmari AK; Ullah Z; Tariq M; Fatani A
Drug Des Devel Ther; 2016; 10():205-15. PubMed ID: 26834457
[TBL] [Abstract][Full Text] [Related]
66. Organic nanocarriers for cancer drug delivery.
López-Dávila V; Seifalian AM; Loizidou M
Curr Opin Pharmacol; 2012 Aug; 12(4):414-9. PubMed ID: 22465543
[TBL] [Abstract][Full Text] [Related]
67. Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors.
Katare OP; Raza K; Singh B; Dogra S
Indian J Dermatol Venereol Leprol; 2010; 76(6):612-21. PubMed ID: 21079304
[TBL] [Abstract][Full Text] [Related]
68. Mucosal drug delivery: membranes, methodologies, and applications.
Song Y; Wang Y; Thakur R; Meidan VM; Michniak B
Crit Rev Ther Drug Carrier Syst; 2004; 21(3):195-256. PubMed ID: 15248809
[TBL] [Abstract][Full Text] [Related]
69. Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers.
Li N; Peng LH; Chen X; Nakagawa S; Gao JQ
Vaccine; 2011 Aug; 29(37):6179-90. PubMed ID: 21740946
[TBL] [Abstract][Full Text] [Related]
70. A review on novel vesicular drug delivery: proniosomes.
Yasam VR; Jakki SL; Natarajan J; Kuppusamy G
Drug Deliv; 2014 Jun; 21(4):243-9. PubMed ID: 24128089
[TBL] [Abstract][Full Text] [Related]
71. Cationic liposomes as in vivo delivery vehicles.
Smyth Templeton N
Curr Med Chem; 2003 Jul; 10(14):1279-87. PubMed ID: 12678799
[TBL] [Abstract][Full Text] [Related]
72. The physiology of cardiovascular disease and innovative liposomal platforms for therapy.
Ruiz-Esparza GU; Flores-Arredondo JH; Segura-Ibarra V; Torre-Amione G; Ferrari M; Blanco E; Serda RE
Int J Nanomedicine; 2013; 8():629-40. PubMed ID: 23413209
[TBL] [Abstract][Full Text] [Related]
73. Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology.
Angst MS; Drover DR
Clin Pharmacokinet; 2006; 45(12):1153-76. PubMed ID: 17112293
[TBL] [Abstract][Full Text] [Related]
74. Intraocular distribution of topically applied hydrophilic and lipophilic substances in rat eyes.
Abdul Nasir NA; Agarwal P; Agarwal R; Iezhitsa I; Alyautdin R; Nukolova NN; Chekhonin VP; Mohd Ismail N
Drug Deliv; 2016 Oct; 23(8):2765-2771. PubMed ID: 26289215
[TBL] [Abstract][Full Text] [Related]
75. Lipid-Based Nanoparticulate Systems for the Ocular Delivery of Bioactives with Anti-Inflammatory Properties.
Ana RD; Fonseca J; Karczewski J; Silva AM; Zielińska A; Souto EB
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36292951
[TBL] [Abstract][Full Text] [Related]
76. Emerging potential of stimulus-responsive nanosized anticancer drug delivery systems for systemic applications.
Ruttala HB; Ramasamy T; Madeshwaran T; Hiep TT; Kandasamy U; Oh KT; Choi HG; Yong CS; Kim JO
Arch Pharm Res; 2018 Feb; 41(2):111-129. PubMed ID: 29214601
[TBL] [Abstract][Full Text] [Related]
77. Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications.
Rudokas M; Najlah M; Alhnan MA; Elhissi A
Med Princ Pract; 2016; 25 Suppl 2(Suppl 2):60-72. PubMed ID: 26938856
[TBL] [Abstract][Full Text] [Related]
78. Oligonucleotide delivery to tumours using macromolecular carriers.
Dass CR
Biotechnol Appl Biochem; 2004 Oct; 40(Pt 2):113-22. PubMed ID: 15070400
[TBL] [Abstract][Full Text] [Related]
79. Nanoparticle formulations in pulmonary drug delivery.
Bailey MM; Berkland CJ
Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
[TBL] [Abstract][Full Text] [Related]
80. The Challenge of Nanovesicles for Selective Topical Delivery for Acne Treatment: Enhancing Absorption Whilst Avoiding Toxicity.
Mancuso A; Cristiano MC; Fresta M; Paolino D
Int J Nanomedicine; 2020; 15():9197-9210. PubMed ID: 33239876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
